Oak Review: Two GH Peptides, and a Price for Neither

Oak is a longevity telehealth platform, and until we read its own checkout data we had it filed — as most of the internet still does — as a weight-loss company with no peptide line. That was wrong. Oak runs six programmes off one checkout, and two of them are squarely on this site's subject: an injectable programme its own patient-consent text names for sermorelin and tesamorelin, and a separate anti-aging programme covering NAD+, glutathione, MIC+B12 and metformin.

Tesamorelin is the part worth stopping on. It is the only GHRH analogue with Phase III trials and an FDA approval behind it, and exactly one other provider on our sermorelin board sells it. That single fact is why Oak has a row on our board at all.

And then there is the other half of this review, which is that Oak will not tell you what any of it costs.

No price, anywhere, for anything except weight loss

This is not a case of a price being hard to find. We pulled Oak's own unauthenticated checkout configuration — the file its quiz reads to build itself — and every one of the six programmes returns a zero price and a zero per-fill charge, with a flag telling the front end to show a total only. The per-drug endpoint returns nothing for every product id it has. The checkout endpoint refuses an unauthenticated request outright.

So the sermorelin price, the tesamorelin price, the NAD+ price, the glutathione price, the MIC+B12 price, the phentermine price, the erectile-dysfunction prices and the skincare prices are all disclosed only after you have completed the quiz and a clinician has approved you. That is after you have handed over your medical history, not before.

We publish no estimate for it. There is nothing honest to estimate from: the only figures Oak publishes anywhere are for compounded GLP-1s, a different drug class bought for a different reason, and quoting one of those as though it told you something about a peptide would be the exact substitution this site exists to argue against. Our board sorted by published price therefore lists Oak with no figure and sorts it last, alongside the one other provider we track that prices nothing publicly. If you want to know what a month of sermorelin normally runs before you start any intake, what sermorelin costs per month is the range to hold Oak's eventual number against.

Five prices for the one thing it does price

It is worth knowing how Oak behaves on the side where it does publish numbers, because that is the only evidence available about how it handles a price at all. On compounded GLP-1s, the same website carries five mutually inconsistent figures: one pair on the homepage hero and product cards, a different pair in the page's own meta description, a third number in the "how Oak compares" table on the homepage, a fourth in the same comparison table on its weight-loss pages, and a fifth in the homepage FAQ. An unpriced "new patient offer" and a "save up to 60% vs retail" banner run alongside them with no published mechanics.

None of those numbers is a sermorelin price and none of them appears on this page for that reason. They matter here only as a track record: a company that publishes five different prices for the product it advertises is not a company whose unpublished price you should assume is the friendly one.

What is actually in the peptide programme

Oak's own consent text for the injectable programme names sermorelin and tesamorelin. Both are growth-hormone-releasing hormone analogues — they prompt your pituitary to release its own GH in pulses rather than replacing the hormone — but they are not interchangeable, and the difference is much bigger than the shared mechanism suggests.

Sermorelin is GHRH(1-29). It raises GH and IGF-1 reliably in the short term¹², and the sleep effect this site is built around is real: GHRH given to healthy men measurably increases slow-wave sleep alongside the GH pulse³, and GHRH's role in sleep regulation is well described⁴. What does not exist is a modern long-term outcome trial in healthy adults⁵.

Tesamorelin is a stabilised GHRH analogue with a genuine Phase III record — but every one of those trials was in HIV-associated lipodystrophy, which is the only condition it is FDA-approved to treat⁶⁷⁸⁹. None of them measured sleep. Buying tesamorelin from a telehealth platform for sleep or recovery is off-label extrapolation from a stronger evidence base pointed somewhere else entirely, and we work that through in tesamorelin vs sermorelin. Because Oak publishes no figure, it also cannot be compared against the market on what tesamorelin costs, where the branded product's price is the thing that makes compounded pricing worth checking.

Also in Oak's catalogue but not purchasable: two vitamin packs, a "Gut Health" one and a "Longevity" one containing NMN, AKG, glycine, hyaluronic acid, omega-3 and vitamin D. Both are built, both carry a price of $165 in the data, and both are flagged inactive with an empty product list. They cannot be bought and they are not listed here as though they could.

Who Oak is, which is a harder question than it should be

Oak's single terms-of-use page carries four different legal entities: Oak Longevity Holdings Corp, Oak Longevity Corp, Leaf Longevity Holdings Corp DBA Oak Longevity, and Oaklovesyou LLC — the last of those inside a second Terms of Use, separately dated, appended below the first. Its homepage footer adds two more: Flow Longevity Holdings Corp and Mito Health Holdings Corp. That is six corporate names across two documents.

We are not alleging anything by pointing that out. We are saying that if you needed to know which company you had contracted with, the documents that are supposed to tell you name six.

Beyond that, Oak publishes less about who makes and who prescribes its medicine than any provider we have verified — and, unlike some of the providers we review, this really is a case of nothing being published rather than us failing to find it:

• •No compounding pharmacy is named. A compounded product is only as good as the facility that makes it, and there is no facility to look up.
• •No clinician is named. No medical director, no physician bios, no NPI. The consent data reveals the prescribing network behind the platform, but Oak's own pages name nobody.
• •No certification you can check. The footer badge links to a certificate checker and renders a locally-hosted image; there is no seal number anywhere in the markup, so there is nothing to verify. We do not describe Oak as certified, and neither should anyone else quoting this page.

Our guide to vetting a sermorelin provider treats a named pharmacy and a named prescriber as two of the three non-negotiables. Oak publishes neither.

Where you can get it, if anywhere

This one is close to circular. One of Oak's two terms documents says the service is provided in 45 states. The other says eligibility depends on a "states where we currently operate" list to be found in our FAQ — and Oak has no FAQ. Every plausible URL for one returns a 404, and its sitemap contains no FAQ page at all. So the authoritative state list is a reference to a document that does not exist.

There is a second inconsistency in the same area. The homepage ships live Women's Health and tadalafil tiles while other pages label men's and women's health "coming soon" — and the Women's Health tile is wired to the anti-aging programme, so a woman clicking "Women's Health" lands in the NAD+ and glutathione intake. There is no women's-health questionnaire in the catalogue at all.

Subscriptions, and refunds

Oak's hero says "No subscriptions" — four times. Its terms describe a subscription fee that may change from time to time and that you may cancel. Both cannot be true, and the terms are the document you are bound by.

The refund position is unambiguous and it is hard: once a provider has approved and prescribed your treatment and the order has reached the pharmacy, it cannot be cancelled and is not refundable — explicitly including any attempt to stop, hold, reroute, return or cancel the shipment with the courier directly. Disputes go to binding individual arbitration and class actions are waived. Combine that with a price you do not learn until the clinician has approved you, and the order of operations is worth saying out loud: you find out what it costs at roughly the same moment the money stops being refundable.

If you are going to use it anyway

There is a version of this that makes sense. Tesamorelin is genuinely hard to get from a consumer telehealth service, and if that specific molecule is what you want, Oak is one of very few places carrying it. If that is you:

• •Get the price in writing at the dose you are actually prescribed, before you authorise anything.
• •Ask which pharmacy fills it and whether it is a 503A. If the answer is "a licensed US pharmacy", that is not an answer.
• •Ask which state licence your prescriber holds, given the state list is a dead link.
• •Get a baseline IGF-1 drawn before the first injection. Nothing in Oak's flow requires it, and without it there is no number to show that anything changed — see sermorelin labs and IGF-1 monitoring.
• •Read who should not take sermorelin first. The cancer-history question is not a formality on either of these molecules.

Bottom line

Oak sells two growth-hormone peptides, one of which — tesamorelin — is genuinely uncommon and genuinely better evidenced than the peptide most of this category sells. That is a real reason to look. Everything else about the company is a reason to look carefully: no published price for any of it, no named pharmacy, no named clinician, no verifiable certification, six legal entities across its terms page and its footer, a state list that points at a missing page, a "no subscriptions" promise its own terms contradict, and a refund policy that closes the door at the pharmacy. If you go, go with the price in writing and the pharmacy named. If you would rather start from providers that publish both, our sermorelin board and where to buy sermorelin online are the places to do it.